A carregar...
Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months
Eribulin is a non-taxane microtubule inhibitor approved for the treatment of metastatic breast carcinoma after two prior chemotherapeutic regimens. We report a patient with extended progression-free survival (PFS) of more than 57 months with metastatic breast carcinoma treated with eribulin in the t...
Na minha lista:
| Publicado no: | Cureus |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cureus
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7075509/ https://ncbi.nlm.nih.gov/pubmed/32201658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.6980 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|